TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. lowered its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 61.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,526 shares of the company’s stock after selling 10,449 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in TransMedics Group were worth $515,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Harbour Capital Advisors LLC boosted its position in TransMedics Group by 1.7% in the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock valued at $627,000 after buying an additional 140 shares during the last quarter. RiverPark Advisors LLC boosted its position in TransMedics Group by 19.5% in the fourth quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after buying an additional 215 shares during the last quarter. Park Avenue Securities LLC boosted its position in TransMedics Group by 3.9% in the third quarter. Park Avenue Securities LLC now owns 11,729 shares of the company’s stock valued at $642,000 after buying an additional 442 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in TransMedics Group by 7.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,396 shares of the company’s stock valued at $584,000 after buying an additional 483 shares during the last quarter. Finally, Van ECK Associates Corp boosted its position in TransMedics Group by 39.0% in the third quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock valued at $116,000 after buying an additional 597 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Activity

In other news, CFO Stephen Gordon sold 15,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $74.01, for a total transaction of $1,110,150.00. Following the transaction, the chief financial officer now owns 23,299 shares in the company, valued at approximately $1,724,358.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CFO Stephen Gordon sold 15,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $74.01, for a total value of $1,110,150.00. Following the completion of the transaction, the chief financial officer now directly owns 23,299 shares of the company’s stock, valued at approximately $1,724,358.99. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Waleed H. Hassanein sold 12,000 shares of the stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The disclosure for this sale can be found here. Insiders have sold 117,078 shares of company stock worth $9,972,971 in the last quarter. Corporate insiders own 6.70% of the company’s stock.

TransMedics Group Trading Up 4.7 %

Shares of NASDAQ:TMDX opened at $90.60 on Wednesday. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $99.63. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The business’s 50 day moving average price is $82.95 and its 200-day moving average price is $74.01.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The firm had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. During the same quarter last year, the firm posted ($0.21) EPS. The business’s revenue was up 158.6% on a year-over-year basis. Research analysts anticipate that TransMedics Group, Inc. will post -0.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of recent research reports. Piper Sandler initiated coverage on TransMedics Group in a research report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 target price on the stock. JPMorgan Chase & Co. upped their target price on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Oppenheimer upped their price objective on TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley upped their price objective on TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.